DDInter1352 DDInter1376
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Osimertinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Osimertinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Osimertinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tazemetostat
Osimertinib {u} may lead to a major life threatening interaction when taken with {v} Tetrabenazine
Osimertinib {u} may lead to a major life threatening interaction when taken with {v} Entrectinib
Osimertinib may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Osimertinib may lead to a major life threatening interaction when taken with Tetrabenazine
Osimertinib may lead to a major life threatening interaction when taken with Entrectinib